Whitsett Jeffrey A, Wert Susan E, Weaver Timothy E
Divisions of Neonatology, Perinatal Biology, and Pulmonary Biology, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229; email:
Annu Rev Pathol. 2015;10:371-93. doi: 10.1146/annurev-pathol-012513-104644.
Advances in physiology and biochemistry have provided fundamental insights into the role of pulmonary surfactant in the pathogenesis and treatment of preterm infants with respiratory distress syndrome. Identification of the surfactant proteins, lipid transporters, and transcriptional networks regulating their expression has provided the tools and insights needed to discern the molecular and cellular processes regulating the production and function of pulmonary surfactant prior to and after birth. Mutations in genes regulating surfactant homeostasis have been associated with severe lung disease in neonates and older infants. Biophysical and transgenic mouse models have provided insight into the mechanisms underlying surfactant protein and alveolar homeostasis. These studies have provided the framework for understanding the structure and function of pulmonary surfactant, which has informed understanding of the pathogenesis of diverse pulmonary disorders previously considered idiopathic. This review considers the pulmonary surfactant system and the genetic causes of acute and chronic lung disease caused by disruption of alveolar homeostasis.
生理学和生物化学的进展为肺表面活性物质在早产呼吸窘迫综合征发病机制和治疗中的作用提供了基本见解。表面活性物质蛋白、脂质转运蛋白以及调节其表达的转录网络的鉴定,为识别出生前后调节肺表面活性物质产生和功能的分子和细胞过程提供了所需的工具和见解。调节表面活性物质稳态的基因突变与新生儿和大龄婴儿的严重肺部疾病有关。生物物理和转基因小鼠模型为深入了解表面活性物质蛋白和肺泡稳态的潜在机制提供了帮助。这些研究为理解肺表面活性物质的结构和功能提供了框架,有助于理解以前被认为是特发性的各种肺部疾病的发病机制。本综述探讨了肺表面活性物质系统以及由肺泡稳态破坏引起的急慢性肺部疾病的遗传原因。